Drug intelligence / Profile preview

RA-1

Development stage: Preclinical
Modality: Peptides

Overview

RA-1 is a novel peptoid designed from the hydrophobic stretch of the Amyloid-β42 (Aβ42) peptide, specifically the 16KLVFFA21 sequence. It is being investigated as a potential therapeutic lead for Alzheimer's disease. RA-1 functions by inhibiting the aggregation of toxic Aβ42 peptides, stabilizing microtubules, reducing the production of cytotoxic reactive oxygen species (ROS), and promoting neurite outgrowth. In preclinical studies, it has demonstrated the ability to improve cognitive ability and memory impairment in animal models of dementia.

Targets

Aβ42 (Amyloid-beta peptide 42)Microtubule

Beyond the preview

Go deeper on RA-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RA-1.

Explore the full profile